Cargando…
Efficacy and Safety of Albumin-Bound Paclitaxel Compared to Docetaxel as Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer
BACKGROUND: Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as neoadjuvant chemotherapy (NAC) for breast cancer remains controversial. We conducted a retrospective study to compare the efficacy and safety of nab-paclitaxel with those of docetaxel as neoadjuvant regimens for HER2-negative brea...
Autores principales: | Lv, Zhi-Dong, Song, Hong-Ming, Niu, Zhao-He, Nie, Gang, Zheng, Shuai, Xu, Ying-Ying, Gong, Wei, Wang, Hai-Bo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787090/ https://www.ncbi.nlm.nih.gov/pubmed/35087749 http://dx.doi.org/10.3389/fonc.2021.760655 |
Ejemplares similares
-
Camrelizumab Combined With Gemcitabine and Albumin-Bound Paclitaxel for Neoadjuvant Therapy in the Treatment of Progressive Gallbladder Cancer: A Case Report
por: Wu, Jing, et al.
Publicado: (2022) -
Albumin-Bound Paclitaxel: Worthy of Further Study in Sarcomas
por: Tian, Zhichao, et al.
Publicado: (2022) -
Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis
por: Zong, Yu, et al.
Publicado: (2017) -
Efficacy evaluation of albumin-bound paclitaxel combined with carboplatin as neoadjuvant chemotherapy for primary epithelial ovarian cancer
por: Wang, Huan, et al.
Publicado: (2022) -
Human clinical trial using diagnostic ultrasound and microbubbles to enhance neoadjuvant chemotherapy in HER2- negative breast cancer
por: Zhou, Biqiang, et al.
Publicado: (2022)